A phase IIa study investigated efficacy and safety/tolerability of ascending doses of mavrilimumab ( anti-granulocyte-macrophage colony-stimulating factor receptor [ GM-CSFR ] monoclonal antibody ) in adult subjects with moderate to severe rheumatoid arthritis from Japan and Europe .